Skip to main content
. Author manuscript; available in PMC: 2015 Jan 22.
Published in final edited form as: J Allergy Clin Immunol. 2013 Jun 20;132(4):906–11.e1-4. doi: 10.1016/j.jaci.2013.04.056

Figure 4.

Figure 4

Recovery of baseline sensitivity after cessation of omalizumab treatment (n=7); (Inline graphic) average baseline sensitivity curve for the 7 subjects that completed the recovery period, (Inline graphic) average sensitivity curve at 12 weeks, (Inline graphic) average sensitivity curve 3 months after cessation of omalizumab.